The U.S. Food and Drug Administration today announced it has awarded 15 grants totaling more than $14 million to boost the development of products for patients with rare diseases. The Orphan Drug Act was passed in 1983 to stimulate the development of products to treat rare diseases and conditions. UTMB’s Dr. Karl Anderson was awarded about $1.5 million over four years for a phase 2 study of hemin for the treatment and prevention of porphyria attacks.